Singapore, Jan. 19 -- China-based startup Zonsen PepLib Biotech Inc. has entered into a worldwide license agreement with Novartis for an undisclosed peptide-based asset in the field of radioligand therapies (RLTs).

Under the agreement, Novartis has obtained an exclusive worldwide license and will be responsible for the development and commercialisation activities for the asset.

The asset has been developed internally by PepLib to date. Through this transaction, Novartis, an experienced global leader in RLTs, will advance the programme to its next stage of development. The asset is expected to complement Novartis' existing RLT portfolio and to leverage the company's strong capabilities in the field to potentially bring a new targeted tre...